Back to Newsroom

Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference

BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, announced today that the Company will present at the 14th Annual Noble Capital Markets Investor Conference being held January 29 & 30, 2018 in Boca Raton, FL. Spiro Rombotis, President & Chief Executive Officer will provide an overview of the Company and progress in key programs.